DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.

Autor: Noguera-Castells A; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain.; Department of Biosciences, Faculty of Science, Technology and Engineering, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain., Campillo-Marcos I; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain., Davalos V; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain., García-Prieto CA; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain.; Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Catalonia, Spain., Valcárcel D; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain., Molero A; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain., Palomo L; Department of Hematology, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain., Gattermann N; Department of Hematology, Oncology and Clinical Immunology, University Cancer Center, Universitätsklinikum Düsseldorf, Düsseldorf, Germany., Wulfert M; Department of Hematology, Oncology and Clinical Immunology, University Cancer Center, Universitätsklinikum Düsseldorf, Düsseldorf, Germany., Chaparro-González L; Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain., Solé F; Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain., Cabezón M; Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, UAB, Badalona, Catalonia, Spain.; Myeloid neoplasms Research Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain., Jiménez-Lorenzo MJ; Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, UAB, Badalona, Catalonia, Spain.; Myeloid neoplasms Research Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain., Xicoy B; Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, UAB, Badalona, Catalonia, Spain.; Myeloid neoplasms Research Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain., Zamora L; Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, UAB, Badalona, Catalonia, Spain.; Myeloid neoplasms Research Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain., De Stefano A; Cellular Signalling Laboratory, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Casalin I; Cellular Signalling Laboratory, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Finelli C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology 'Seràgnoli', Bologna, Italy., Follo MY; Cellular Signalling Laboratory, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Esteller M; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1838-1843. Date of Electronic Publication: 2024 Mar 12.
DOI: 10.1111/bjh.19392
Abstrakt: Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.
(© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: